miR-155 accelerates the growth of human liver cancer cells by activating CDK2 via targeting H3F3A

Xiaoru Xin,1,3 Yanan Lu,1,3 Sijie Xie,1,3 Yingjie Chen,1 Xiaoxue Jiang,1 Shuting Song,1 Liyan Wang,1 Hu Pu,1 Xin Gui,1 Tianming Li,2 Jie Xu,2 Jiao Li,3 Song Jia,3 and Dongdong Lu1

1Shanghai Putuo District People’s Hospital, School of Life Science and Technology, Tongji University, Shanghai 200092, China; 2School of Medicine, Tongji University, Shanghai 200092, China

miR-155 is associated with the promotion of tumorigenesis. Herein, we indicate that abnormal miR-155 was negatively correlated with the expression of P21WAF1/Cip1. Our results suggest that miR-155 alters the transcriptome and inhibits the expression of H3F3A in liver cancer cells. Therefore, miR-155 inhibits the methylation modification of histone H3 on the 27th lysine. Notably, on the one hand, miR-155-dependent CTCF loops cause the CDK2 interacting with cyclin E in liver cancer cells; on the other hand, miR-155 promotes the phosphorylation modification of CDK2 by inhibiting H3F3A. Subsequently, miR-155 competitively blocks the binding of RNA polymerase II (RNA Pol II) to the P21WAF1/CIP1 promoter by increasing the phosphorylation of CDK2, inhibiting the transcription and translation of P21WAF1/CIP1. Strikingly, excessive P21WAF1/CIP1 abolishes the cancerous function of miR-155. In conclusion, miR-155 can play a positive role in the development of liver cancer and influence a series of gene expression through epigenetic regulation.

RESULTS

miR-155 promotes progression of human liver cancer cells

To investigate the effect of miR-155 on hepatoma cells, the miR-155 (RefSeq: MI0000681) precursor sequence (CUGUUAUGCG UAAUCUGAUAGGG GUUUUUGCCUCCAUCAGUCAUACUGACUCUCAAUAAACUGACUCCUA GUUUUUGCCUCCAUCAGUCAUACUGACUCUCAAUAAACUGACUCCUA) was cloned into the lentiviral vector pLVX-ZsGreen-miRNA-Puro to construct a recombinant lentiviral framework plasmid pLVX-ZsGreen-miR-155-puro (pLVX-miR-155). The recombinant plasmid pLVX-miR-155 was then packaged into a lentivirus, resulting in a high-titer lentiviral rLV-ZsGreen-miR-155-Puro (rLV-miR-155) and rLV-miR-155. To investigate the effect of miR-155 on human hepatoma cells, rLV-miR-155 or rLV was infected into liver cancer cell line Hep3B. The two stable cell lines (rLV-Hep3B and rLV-miR-155-Hep3B) expressed green fluorescent protein (Figure 1A, Green). The miR-155 precursor and mature miR-155 were significantly increased in the rLV-miR-155 group compared with those

INTRODUCTION

MicroRNAs (miRNAs) are a class of small non-coding RNAs that are endogenous regulators of gene expression.1–5 At present, miRNAs have been shown to play an important role in many biological responses, and the dysfunction of miRNAs is associated with several human diseases, especially tumors.1,6

Several studies have reported that miR-155 is closely related to inflammation.7,8 Other studies have found that miR-155 can promote the progression of human leukemia and is one of the key factors for leukemia. Moreover, miR-155 is also closely related to tumors.9–15 Especially, it has been found that miR-155 is upregulated in the liver tissues of patients.16–18 So far, the role of miR-155 in the development of human liver cancer has not been clarified. Therefore, it is important to clarify the mechanism of miR-155 in the hepatocarcinogenesis.

Studies have shown that epigenetic regulation is closely related to tumorigenesis. Histone H3 modification is the most widely studied, and its biological significance of some modifications has been well characterized.19 For example, acetylation of lysine (H3K14) at position 14 of H3, methylation of lysine at position 4 (H3K4), and phosphorylation of serine at position 10 (H3S10) cause activation of gene transcription.20–22 In contrast, methylation of H3K9 and H3K27 is often associated with gene suppression.23–26 Recently, it has been found that miR-155 can change the transcription initiation site of the serine/arginine-rich splicing factor 2 (SRSF2) promoter and regulate the protein kinase A (PKA) signaling pathway.27 These findings suggest that miR-155 is directly or indirectly involved in epigenetic regulation.

In this study, we found that miR-155 promotes the growth of human hepatoma cell Hep3B. miR-155 inhibits the expression of H3F3A and then reduces the modification level of H3K27me3. These findings provide a theoretical basis for the treatment and diagnosis of human liver cancer.
in the rLV group (Figures 1B–1D). Next, the proliferation ability was significantly increased in the rLV-miR-155 group compared with that in the rLV group (24 h: p = 0.00033 < 0.01; 48 h: p = 0.00046 < 0.01; 72 h: p = 0.00323 < 0.01) (Figure 1E). The positive rate of bromodeoxyuridine (BrdU) (29.47% ± 3.59% versus 58.75% ± 6.59%, p = 0.00438 < 0.01) (Figure 1F), the number of plate colonies formed (21 ± 4.58 versus 840 ± 52.92, p = 0.000803 < 0.01) (Figure 1G), the sphere formation rate (3.04% ± 0.187% versus 8.03% ± 0.743%, p = 0.0031 < 0.01) (Figure 1H), and the rate of autophagy (6.34% ± 1.07% versus 22.49% ± 2.89%, p = 0.00955 < 0.01) (Figures 1Ia and 1Ib) were significantly increased in the rLV-miR-155 group compared with those in the rLV group. Furthermore, Luc activity, as recorded with the Autophagy LC3 HiBiT Reporter Assay, was significantly decreased in the rLV-miR-155 group compared with that in the rLV group (184.24 ± 34.05 versus 14.73 ± 2.24, p = 0.00069 < 0.01) (Figure 1Ic). Moreover, the senescence rate (5.07% ± 1.41% versus 17.15% ± 2.41%, p = 0.0092 < 0.01) (Figures 1Ja and 1Jb) and the senescence factor FBLN1 (1.5 ± 0.19 versus 3.44 ± 0.514, p = 0.00856 < 0.01) (Figure 1Jc) were significantly increased in the rLV-miR-155 group compared with those in the rLV group. Additionally, the average weight of transplanted tumors in nude mice was significantly increased in the rLV-miR-155 group compared with that in the rLV group (0.507 g ± 0.138 g versus 1.658 g ± 1.136 g, p = 0.0263 < 0.05) (Figures 2A–2C). Moreover, poorly differentiated cancer cells in transplanted tumors were significantly increased in the rLV-miR-155-Hep3B group compared with those in the rLV group (Figure 2D). Both the proliferating cell nuclear antigen (PCNA)-positive rate (45.17% ± 4.33% versus 74.27% ± 7.94%, p < 0.01) (Figures 2Ea and 2Eb) and the Ki67-positive rate (33.57% ± 2.89% versus 70.11% ± 6.73%, p < 0.01) (Figure 2Ec) were significantly increased in the rLV-miR-155 group compared with those in the rLV group. Collectively, these results suggest that miR-155 can promote autophagy and cellular senescence, triggering the growth of liver cancer cells in vitro and in vivo.

miR-155 Inhibits the Expression of Histone H3 Variant H3F3A

Given that miR-155 promotes the growth of human hepatoma cells, we will explore the effects of miR-155 on several vital signaling molecules in human hepatoma cells. RNA sequencing analysis showed that there were significant differences in the expression of several genes in the rLV-miR-155 group compared with that in the rLV group. Among

Figure 1. miR-155 Promotes the Growth of Liver Cancer Cell In Vitro
(A) The human hepatocarcinoma cell line Hep3B was infected with rLV-miR-155 and rLV, and the green fluorescent protein (green) was expressed. The positive cells were expanded and then imaged with a fluorescence microscope. (B) The miR-155 precursors in these two stable cell lines were detected by RT-PCR. (C) The expression of miR-155 in these two stable cell lines was detected by northern blotting. (D) qRT-PCR was used to detect mature miR-155. (E) The growth curve was determined by the CCK8 method. (F) Determination of S phase was determined by the BrdU method. OD450, optical density 450. (G) Determination of plate colony-forming ability. (a) Photograph of plate colonies. (b) Analysis of the formation of cell plate colonies. (H) Determination of cell-sphere formation ability. (a) Photograph of cell spheres. (b) Determination of cell-sphere formation rate. (I) Determination of autophagy formation ability of cells. (a) Photograph of cell autophagy. (b) Determination of cell autophagy rate. (c) Autophagy LC3 HiBiT Reporter Luc assay analysis. (J) Cellular senescence assay of cells. (a) Photograph of cell senescence. (b) Determination of cell senescence.
them, 191 genes were upregulated and 284 genes were downregulated, including RPLP0, EIF4G2, YBX1, EEF1A1P5, EEF1A1, HNRNPA3, YWHAE, MIR30A, SMAD7, CALR, S100A6, TPT1, THBS1, and PSMB7 (downregulated expression) and HSPA5, CALM3, H3.3, and P21WAF1/Cip1 (downregulated expression) (Figure 3A). The miR-155 binds to the histone variant H3F3A mRNA 3’ untranslated region (UTR) via a 12-base seed sequence (Figure 3B). pMirtarget-H3F3A 3’ UTR-Luc luciferase reporter gene activity was significantly decreased in the rLV-miR-155 group compared with that in the rLV group (p < 0.01) (Figure 3C). Furthermore, although there was no significant change in the transcriptional capacity of H3F3A (Figure 3D), the translational capacity of H3F3A was significantly attenuated in the rLV-miR-155 group compared with that in the rLV group (Figure 3E). Collectively, these results suggest that miR-155 inhibits the expression of H3F3A in liver cancer cells.

miR-155 Inhibits the Methylation Modification of Histone H3 on the 27th Lysine

Given that miR-155 inhibits the expression of histone H3F3A, we will consider whether miR-155 affects the methylation of lysine at position 27 of histone H3 by inhibiting H3F3A. Compared with the rLV-Hep3B group, the interaction between histone H3 and EZH2, SUZ12, EED, and RbAp46/48 was attenuated in the rLV-miR-155 group (Figure 4A). In particular, the interaction between EZH2 and SUZ12, EED, and RbAp46/48 was not significantly changed in the rLV-miR-155+rLV-H3.3 group compared with that in the rLV group (Figures 4B and 4C). Moreover, although the interaction of histone H3 with EZH2, SUZ12, EED, and RbAp46/48 was attenuated in the rLV-miR-155 group compared with that in the rLV group, it was not significantly altered in the rLV-miR-155+rLV-H3F3A-Hep3B group compared with the rLV group (Figure 4D). Finally, although H3K27me1, H3K27me2, and H3K27me3 were significantly reduced in the rLV-miR-155 group compared with the rLV group, they were not significantly altered in the rLV-miR-155+rLV-H3F3A-Hep3B group compared with the rLV group (Figures 4E and 4F). Collectively, these results suggest that miR-155 inhibits the methylation modification of histone H3 on the 27th lysine.
miR-155 Promotes the Expression of CDK2 by Inhibiting H3F3A

Given that miR-155 inhibits the expression of H3F3A, we will investigate whether miR-155 affects the expression of CDK2 dependent on H3F3A in human liver cancer cells. The ability of H3K27me1, H3K27me2, and H3K27me3 to bind to the CDK2 promoter region was significantly reduced in the rLV-miR-155 group compared with that in the rLV group (Figures 5A and 5B). pEZX-MT-CDK2 promoter-Luc luciferase reporter gene activity was significantly increased in the rLV-miR-155 group compared with that in the rLV group (26,379.94 ± 4,467.87 versus 271,502.52 ± 37,169.69, p = 0.0045388 < 0.01) (Figure 5C). Moreover, the expression of CDK2 was significantly increased in the rLV-miR-155 group compared with that in the rLV group (Figures 5D and 5E). Furthermore, although the ability of H3K27me1, H3K27me2, and H3K27me3 to bind to the CDK2 promoter region was significantly reduced in the rLV-miR-155 group compared with that in the rLV group, it was not significantly changed in the miR-155+rLV-H3F3A group compared with that in the rLV group (Figure 8F). Although the ability of H3K27me3 to bind to the CDK2 promoter cis-element probe was significantly reduced in the rLV-miR-155 group compared with that in the rLV group, it was not significantly changed in the miR-155+rLV-H3F3A group compared with that in the rLV group (Figures 5G). Although the pEZX-MT-CDK2 promoter-Luc luciferase reporter activity was significantly increased in the rLV-miR-155 group compared with that in the rLV group (45,050.5 ± 8,371.58 versus 244,546.37 ± 11,240.85, p = 0.00035832 < 0.01), it was not significantly altered in the miR-155+rLV-H3F3A group compared with the rLV group (45,050.5 ± 8,371.58 versus 38,966.22 ± 3,915.22, p = 0.07138 > 0.05) (Figure 5H). Although the expression of CDK2 was significantly increased in the rLV-miR-155 group compared with that in the rLV group, it was not significantly changed in the miR-155+rLV-H3F3A group compared with that in the rLV group (Figures 5I and 5J). Collectively, these results suggest that miR-155 enhances the expression of CDK2 by inhibiting H3F3A.

miR-155 Inhibits Phosphorylation of CDK2

Given that miR-155-dependent H3F3A inhibits the expression of CDK2 in human liver cancer cells, we considered whether miR-155 affects the phosphorylation of CDK2. First, the ability of CTCF to bind to pre-miR-155 was significantly increased in the rLV-miR-155 group compared with that in the rLV group (Figure 6A). Thereby, the cyclized pre-miR-155 was significantly increased in the rLV-miR-155 group compared with that in the rLV group (Figures 6B–6D). Furthermore, the ability of CDK2 or cyclin E to bind to pre-miR-155 was significantly increased in the rLV-miR-155 group compared with that in the rLV group (Figure 6E). Thus, the capacity of CDK2 to bind to cyclin E was significantly increased in the rLV-miR-155 group.
compared with that in the rLV group (Figure 6F). Ultimately, phosphorylated CDK2 (pCDK2) was significantly increased in the rLV-miR-155 group compared with the rLV group (Figure 6G).

Furthermore, although the ability of CTCF to bind to pre-miR-155 was significantly increased in the rLV-miR-155 group compared with that in the rLV group, it was significantly reduced in the rLV-miR-155+pGFP-V-RS-CTCF group compared with that in the rLV group and not changed in the miR-155+rLV-HF3A group (Figure 6I). Moreover, the ability of CDK2 or cyclin E to bind to pre-miR-155 was significantly increased in the rLV-miR-155 group compared with that in the rLV group; however, the ability of CDK2 or cyclin E to bind to pre-miR-155 was significantly reduced in the rLV-miR-155+pGFP-V-RS-CTCF group, and there was no significant change in the rLV-miR-155+rLV-H3.3 group compared with the rLV group (Figure 6J). In particular, the ability of CDK2 or cyclin E to bind to pre-miR-155 was significantly increased in the rLV-miR-155 group compared with that in the rLV group.
reduced in the rLV-miR-155+pGFP-V-RS-CTCF group, and there was no significant change in the rLV-miR-155+rLV-H3.3 group compared with the rLV group (Figure 6K). Therefore, pCDK2 was significantly increased in the rLV-miR-155 group compared with that in the rLV group. However, the phosphorylation of CDK2 was significantly reduced in the rLV-miR-155+pGFP-V-RS-CTCF group, and there was no significant change in the rLV-miR-155+rLV-H3.3 group compared with the rLV group (Figure 6L). Collectively, these results suggest that, on the one hand, miR-155-dependent CTCF loops cause the CDK2 interaction with cyclin E and that, on the other hand, miR-155 promotes the phosphorylation modification of CDK2 by inhibiting H3F3A in liver cancer cells.

miR-155 Inhibits the Expression of Tumor Suppressor Gene P21WAF1/CIP1

Given that miR-155 promotes the expression of CDK2 and its phosphorylation modification in liver cancer cells, we attempted to analyze whether miR-155 affects the expression of the tumor suppressor gene P21WAF1/CIP1 via pCDK2. Although the ability of pCDK to bind to the P21WAF1/CIP1 promoter region was significantly increased in the rLV-miR-155 group compared with that in the rLV group, it was not significantly changed in the rLV-miR-155+pGFP-V-RS-CTCF group compared with that in the rLV group (Figure 7A). Although the ability of pCDK to bind to the P21WAF1/CIP1 promoter region was significantly increased in the rLV-miR-155 group compared with that in the rLV group, it was not significantly changed in the miR-155+rLV-H3F3A group compared with that in the rLV group (Figure 7B). The capacity of RNA polymerase II (RNA Pol II) to bind to the P21WAF1/CIP1 promoter region was significantly decreased in the rLV-miR-155 group compared with that in the rLV group. However, there was no significant change in the capacity of RNA Pol II to bind to the P21WAF1/CIP1 promoter region in the rLV-miR-155+rLV-H3F3A group compared with that in the rLV group (Figure 7C). Although the ability of RNA Pol II to bind to the P21WAF1/CIP1 promoter region was significantly reduced in the rLV-miR-155 group, compared with that in the rLV group, it was not significantly changed in the miR-155+pGFP-V-RS-CTCF group compared with that in the rLV group (Figure 7D). The ability of pCDK2 to bind to the P21WAF1/CIP1 promoter region was significantly increased in the rLV-miR-155+pGFP-V-RS-CTCF group compared with that in the rLV group. However, there was no significant change in the capacity of pCDK2 to bind to the P21WAF1/CIP1 promoter region in the rLV-miR-155+rLV-H3F3A group and the rLV-miR-155+pGFP-V-RS-CTCF group compared with that in the rLV group (Figure 7E). Although the ability of RNA Pol II to bind to the...
The P21WAF1/CIP1 promoter cis-element probe was significantly reduced compared with that in the rLV group, it was not significantly changed in the rLV-miR-155+rLV-H3F3A group and the miR-155+pGFP-V-RS-CTCF group compared with that in the rLV group (Figure 7F). The ability of pCDK2 to bind to the P21WAF1/CIP1 promoter-enhancer DNA loop was significantly increased in the rLV-miR-155 group compared with that in the rLV group. However, the ability of pCDK2 to bind to the P21WAF1/CIP1 promoter-enhancer loop was not significantly changed in the rLV-miR-155+rLV-H3F3A group and the rLV-miR-155+pGFP-V-RS-CTCF group compared with that in the rLV group (Figure 7F). The ability of pCDK2 to bind to the P21WAF1/CIP1 promoter region was significantly increased, and the ability of RNA Pol II to bind to the P21WAF1/CIP1 promoter region was significantly reduced in the rLV-miR-155 group compared with that in the rLV group. However, these binding abilities were not significantly different from that in the rLV-miR-155+rLV-H3F3A group and the rLV-miR-155+pGFP-V-RS-CTCF group compared with that in the rLV group (25,512.49 ± 4,129.56 versus 25,512.49 ± 4,129.56, p = 0.3233 > 0.05), and the luciferase reporter gene activity in the rLV-miR-155+pGFP-V-RS-CTCF group was not significantly different from that in the rLV group (25,512.49 ± 4,129.56 versus 27,443.78 ± 4,543.94, p = 0.22073 > 0.05) (Figure 7I).

Furthermore, miR-155 was significantly increased in the miR-155 and rLV-miR-155+pGFP-V-RS-CAK (CDK2-activating kinase) groups compared with the rLV group (Figure 7La). pCDK2 (Thr160) was significantly increased in the rLV-miR-155 group compared with that in the rLV group, and pCDK2 (Thr160) and CAK were significantly reduced in the rLV-miR-155+pGFP-V-RS-CAK group compared with that in the rLV group (Figure 7Lb). The phosphorylation of CDK2 was detected by western blotting. c-actin was used as an internal reference gene.
significantly changed in the rLV-miR-155+pGFP-V-RS-CAK group compared with those in the rLV group (Figure 7M). The ability of pCDK2 to bind to the P21WAF1/CIP1 promoter-enhancer loop was significantly increased, and the capacity of RNA Pol II to bind to the P21WAF1/CIP1 promoter-enhancer loop was significantly reduced in the rLV-miR-155 group compared with that in the rLV group. However, these binding abilities were not significantly changed in the rLV-miR-155+pGFP-V-RS-CAK group compared with those in the rLV group (Figure 7N). The pEZX-MT-P21WAF1/CIP1 promoter-Luc luciferase reporter gene activity was significantly decreased in the rLV-miR-155 group compared with that in the rLV group (38,502.61 ± 6,155.78 versus 5,009.03 ± 652.7, p = 0.00671 < 0.01). However, the luciferase reporter gene activity in the rLV-miR-155+pGFP-V-RS-CAK group was not significantly different from that in the rLV group (38,502.61 ± 6,155.78 versus 41,045.93 ± 2,208.55, p = 0.2442 > 0.05) (Figure 7Q). The transcriptional and translational capacity of P21WAF1/CIP1 was significantly reduced in the rLV-miR-155 group compared with that in the rLV group. However, there was no significant change in the rLV-miR-155+pGFP-V-RS-CAK group compared with that in the rLV group. Collectively, these results suggest that miR-155 competitively inhibits the expression of P21WAF1/CIP1 in liver cancer.
Excessive P21WAF1/CIP1 Abolishes the Cancerous Functions of miR-155

In order to further investigate whether miR-155 is dependent on P21WAF1/CIP1 to promote hepatocarcinoma growth, we performed related experiments in the rLV group, the rLV-miR-155 group, and the rLV-miR-155+rLV-P21WAF1/CIP1 group. The mature miR-155 was significantly increased in the rLV-miR-155 group and the rLV-miR-155+rLV-P21WAF1/CIP1 group compared with the rLV group (Figure 8Aa). The expression of P21WAF1/CIP1 was significantly decreased in the rLV-miR-155 group and decreased in the rLV-miR-155+rLV-P21WAF1/CIP1 group compared with the rLV group (Figure 8Ab). Although the proliferation rate was significantly increased in the rLV-miR-155 group compared with that in the rLV group (p < 0.01), it was not significantly changed in the rLV-miR-155+rLV-P21WAF1/CIP1 group compared with that in the rLV group (p = 0.2236 > 0.05) (Figure 8B). The positive rate of BrdU was significantly increased in the rLV-miR-155 group compared with that in the rLV group (27.11% ± 3.61% versus 55.93% ± 8.74%, p = 0.00694 < 0.01). However, the positive rate of BrdU was not significantly altered in the rLV-miR-155+rLV-P21WAF1/CIP1 group compared with that in the rLV group. (27.11% ± 3.61% versus 25.49% ± 6.2%, p = 0.231887 > 0.05) (Figure 8C). Although the colony formation rate was significantly increased in the rLV-miR-155 group compared with that in the rLV group (37.63% ± 4.56% versus 68.59% ± 6.33%, p = 0.00778 < 0.01), the colony formation rate was not significantly altered in the rLV-miR-155+rLV-P21WAF1/CIP1 group compared with that in the rLV group (37.63% ± 4.56% versus 34.07% ± 5.93%, p = 0.2507 > 0.05) (Figure 8D). Although the sphere formation rate was significantly increased in the rLV-miR-155 group compared with that in the rLV group...
Although the expression of PCNA in the transplanted tumor tissues (Figures 8Ga and 8Gb). The average appearance time of transplanted tumor tissues obtained more poorly differentiated tumor cells and fewer moderately differentiated cells in the rLV-miR-155 group and the rLV group (0.893 ± 0.065 versus 2.103 ± 0.1159, p = 0.003814 < 0.01). However, the senescence factor FBLN1 was not significantly altered in the rLV-miR-155+rLV-P21WAF1/CIP1 group compared with the rLV group (0.893 ± 0.065 versus 0.703 ± 0.168, p = 0.1677299 > 0.05) (Figure 8Fc). Although the average weight of transplanted tumors was significantly increased in the rLV-miR-155 group compared with that in the rLV group (0.2275 g ± 0.02915 g versus 1.05375 g ± 0.1207 g, p = 0.000000997 < 0.01), it was not significantly altered in the rLV-miR-155+rLV-P21WAF1/CIP1 group compared with the rLV group (0.2275 g ± 0.02915 g versus 0.20625 g ± 0.037 g, p = 0.097268 > 0.05) (Figures 8Ga and 8Gb). The average appearance time of transplanted tumors was significantly decreased in the rLV-miR-155 group compared with that in the rLV group (9 ± 1.31 days versus 6.125 ± 1.126 days, p = 0.00175 < 0.01). However, it was not significantly altered in the rLV-miR-155+rLV-P21WAF1/CIP1 group compared with the rLV group (9 ± 1.31 days versus 9.625 ± 1.847 days, p = 0.2684 > 0.05) (Figure 8Gc). The transplanted tumor tissues contained more poorly differentiated tumor cells and fewer moderately differentiated cells in the rLV-miR-155 group than in the rLV group; however, there was no significant difference between the rLV-miR-155+rLV-P21WAF1/CIP1 group and the rLV group (Figure 8H).

Although the expression of PCNA in the transplanted tumor tissues was significantly increased in the rLV-miR-155 group compared with that in the rLV group, there was no significant difference between the rLV-miR-155+rLV-P21WAF1/CIP1 group and the rLV group (Figures 8Ia and 8Ib). The expression of PCNA in the transplanted tumor tissues was significantly increased in the rLV-miR-155 group compared with that in the rLV group (42.59% ± 5.49% versus 85.23% ± 6.598%, p = 0.00000911 < 0.01), there was no significant difference in PCNA expression between the rLV-miR-155+ rLV-P21WAF1/CIP1 group and the rLV group (42.59% ± 5.49% versus 40.03% ± 2.75%, p = 0.130044 > 0.05) (Figure 8I). Collectively, these results suggest that excessive P21WAF1/CIP1 abrogates the oncogenic functions of miR-155 in liver cancer.

DISCUSSION

miR-155 is a non-coding miRNA that has a certain relationship with the promotion of tumorigenesis. In this study, we indicate that miR-155 can promote the growth of liver cancer cells in vitro and in vivo and that miR-155 can play a positive role in the development of liver cancer. Moreover, we have demonstrated that miR-155 can influence a series of gene expressions through epigenetic regulation in liver cancer cells (Figure 8K). So far, a novel mechanism has emerged, particularly showing that miR-155 is associated with epigenetic modifications of histones in liver cancer.

First, our results show that miR-155 is highly expressed in human hepatocarcinoma tissues—miR-155, especially, can promote the proliferation of human hepatoma cells Hep3B in vitro and in vivo suggesting that miR-155 has a strong function of causing liver cancer. A number of studies have reported that miR-155 can act as an accelerator to promote the development of acute.9-11 In addition to blood diseases, miR-155 is also closely related to the development of solid tumors. The study found that miR-155 plays a key role in promoting the progression of glioma and can be a prognostic factor for the survival of patients.32 These reports suggest that miR-155 is involved in the regulation of tumor development and plays a carcinogenic role. Therefore, our findings are consistent with these reports.

Second, we found that miR-155 can target H3F3A (also called H3.3) 3’ UTR and inhibit H3F3A translation and that miR-155 can inhibit H3K27me1/2/3 modification and promote CDK2 phosphorylation of p21WAF1/cip1 in liver cancer. Importantly, these functions were fully abolished after increasing the expression of H3F3A in miR-155-overexpressing liver cancer cells, indicating that, at least in liver cancer cells, miR-155 acts through H3F3A. H3F3A has been shown to be a key player in a variety of life activities.33,34 Studies have shown that the deposition of H3F3A dependent on Hira is the key to regulate cell fate transformation. H3F3A plays a role in protecting the identity of parental cells in the early stage of cell reprogramming. In addition, H3F3A and its cleavage products promote transcriptional silence and cellular senescence.35 Graber et al.36 reported overexpression of H3F3A in esophageal and lung cancer cell lines, but the function of H3F3A in tumors has rarely been studied and remains unknown.

Notably, our results show that miR-155 alters the level of histone modification in human liver cancer cells, including the following mechanisms: (1) miR-155 reduces the interaction among EZH2, SUZ12, EED, and RbAp46/48 with histone H3. It is well known that polycomb inhibitor complex-2 (PRC2) is a class of polycomb proteins consisting of four core proteins: SUZ12, EED, and RbAp46/48 with histone H3. (3) miR-155-dependent H3F3A inhibits the level of trimethylation modification on the 2nd lysine of histone H3. (4) miR-155 affects the expression of several genes through changes in the level of H3K27me3 in liver cancer cells, such as CDK2. It is well known that polycomb inhibitor complex-2 (PRC2) is a class of polycomb proteins consisting of four core proteins: SUZ12, EED, and RbAp46/48. Studies have shown that EZH2 can only exert its methyltransferase activity when combined with SUZ12, EED, and RbAp46/48, and EZH228 The trimethylation of H3K27 is particularly dependent on the involvement of SUZ12.28 Thereby, the interaction of these four core components plays an important role in the activity of the PRC2 complex and the methylation modification of PRC2-mediated H3K27me3,29 and a decrease in the level of H3K27me3 modification leads to tumorigenesis.30,31 Therefore, the changes in H3K27me3 modification may be associated with liver cancer.
Strikingly, our results suggest that miR-155 is capable of forming a circular structure and functions in liver cancer cells. These results show that, on the one hand, circular miR-155 binds to cyclin E or pCDK2 and that, on the other hand, circular pre-miR-155 containing cyclin E and pCDK2 forms a topology (to be further proved) by an unknown mechanism, resulting in a direct interaction between pCDK2 and cyclin E. So far, circular RNA (circRNA) is a new class of endogenous non-coding RNAs that are widely found in eukaryotic gene transcripts. In addition, circRNA can also act as a central part of protein interactions. Du et al. have demonstrated that circFoxo3 regulates cell-cycle progression by forming a ternary complex with CDK2 and p21, but so far, there is no report on the role of miR-155 through cyclization. The mechanism for how pre-miR-155 is cyclized and plays roles remains to be further studied.

More importantly, miR-155 relies on H3F3A and H3K27me1/2/3 to alter the expression and function of cyclin in liver cancer cells, including the following mechanisms: (1) miR-155 reduces the level of methylation of histone H3K27 on the cyclin-dependent kinase (CDK)2 promoter region, which enhances the transcription and translation of CDK2; (2) miR-155 promotes phosphorylation of CDK2; (3) miR-155 enhances the binding of pCDK2 to cyclin E by cyclization and promotes the binding of pCDK2-cyclin E to the promoter region of the CDK inhibitor p21 (also known as p21WAF1/Cip1), inhibiting the expression of p21; and (4) excessive p21 abolishes oncogenic functions of miR-155. It is well known that CDK2 is regulated by cyclin E and cyclin A and is necessary for the transition of cells from the G1 phase to the S phase. Activated CDK2 is critical for the abnormal growth of cancer cells. In addition, Tang et al. reported that WTAP can promote the proliferation of renal cancer cells by regulating the stability of CDK2 mRNA and enhancing the expression of CDK2. The CDK inhibitor p21 (or p21WAF1/Cip1) is a well-known cell-cycle inhibitor that is mainly associated with inhibition of CDKs, thereby inhibiting tumor progression. Several reports indicate that p21WAF1/Cip1 inhibits tumorigenesis and other tumor effects. These reports are consistent with our findings. Notably, when CAK for pCDK2 (Thr160) was knocked down in miR-155-overexpressing Hep3B cells, the ability of pCDK2 or RNA Pol II to bind to the P21WAF1/CIP1 promoter region was not significantly changed, and the transcriptional and translational capacity of P21WAF1/CIP1 was also not significantly changed. Therefore, miR-155 competitively blocks the binding of RNA Pol II to the P21WAF1/CIP1 promoter by increasing the phosphorylation of CDK2, inhibiting the expression of P21WAF1/CIP1 in liver cancer.

In conclusion, we need to further explore the impact of miR-155 on the development of human liver cancer and provide a theoretical basis for the prevention and treatment of liver cancer.

**MATERIALS AND METHODS**

**Cell Lines and Lentivirus**

Human hepatoma cell line Hep3B was obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Lentivirus LV-miR and rLV-miR-155 were purchased from Wu Han Viral Therapy Technologies. pGFP-V-RS was purchased from Origene (Rockville, MD, USA).

**RT-PCR**

Total RNA was purified using TRIzol (Invitrogen) according to the manufacturer’s instructions.

**RNA Sequencing Analysis**

RNA sequencing analysis was performed according to the manufacturer’s protocol (Beijing Nuohe Zhiyuan Technology).

**Co-immunoprecipitation (CoIP)**

The immunoprecipitates were incubated with 30 μL protein G/A-plus agarose beads by rotation overnight at 4°C. The precipitates were washed five times with bead wash solution. Western blotting was performed with related antibodies.

**Super-EMSA (Gel Shift)**

Cells were washed and scraped in ice-cold PBS to prepare nuclei for electrophoretic gel mobility shift assay (EMSA) with the use of the gel shift assay system modified according to the manufacturer’s instructions (Promega).

**Cell Proliferation CCK8 Assay**

The cell proliferation was measured using the CCK8 Assay Kit according to the manufacturer’s instructions (Boshide, Wuhan, China).

**Colony-Formation Efficiency Assay**

Cell colonies on the dishes were stained with crystal violet, and the colonies were counted.

**Xenograft Transplantation In Vivo**

Four-week-old athymic BALB/c mice were purchased from Shi Laike (Shanghai, China) and maintained in the Tongji animal facilities approved by the China Association for Accreditation of Laboratory Animal Care. The mice were observed for 4 weeks and then sacrificed to recover the tumors.

**AUTHOR CONTRIBUTIONS**

D.L. conceived the study and participated in the study design, performance, coordination, and manuscript writing. X.X., Y.L., S.X., Y.C., X.J., S.S., L.W., H.P., X.G., T.L., J.X., J.L., and S.J. performed the research. All authors have read and approved the final manuscript.

**CONFLICTS OF INTEREST**

The authors declare no competing interests.

**ACKNOWLEDGMENTS**

This study was supported by a grant from the National Natural Science Foundation of China (NCSF no. 81773158) and by a grant from the Science and Technology Commission of Shanghai Municipality Basic Research Field Project (19JC1415200).
REFERENCES

1. Asano, N., Matsuzaki, J., Ichikawa, M., Kawachi, J., Takizawa, S., Aoki, Y., Sakamoto, H., Yoshida, A., Kobayashi, E., Tanazawa, Y., et al. (2019). A serum microRNA classifier for the diagnosis of sarcomas of various histological subtypes. Nat. Commun. 10, 1239.

2. Bartel, D.P. (2018). Metazoan MicroRNAs. Cell 173, 20–51.

3. Lewis, B.P., Burge, C.R., and Bartel, D.P. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15–20.

4. Meister, G., and Tuschl, T. (2004). Mechanisms of gene silencing by double-stranded RNA. Nature 431, 343–349.

5. Mello, C.C., and Conte, D., Jr. (2004). Revealing the world of RNA interference. Nature 431, 338–342.

6. Tavaullie, R., McCarron, J., Le Grand, M., Ariosti, N., Schuhmann, W., Bakker, E., Tilley, R.D., Hibbert, D.B., Kavalarios, M., and Gooding, J.T. (2018). Nucleic acid hybridization on an electrically reconfigurable network of gold-coated magnetic nanoparticles enables microRNA detection in blood. Nat. Nanotechnol. 13, 1066–1071.

7. Mann, M., Mehta, A., Zhao, J.L., Lee, K., Marinov, G.K., Garcia-Flores, Y., Lu, L.F., Rudensky, A.Y., and Baltimore, D. (2017). An NF-kappaB-microRNA regulatory network tunes macrophage inflammatory responses. Nat. Commun. 8, 851.

8. Alivernini, S., Kuroswa-Stolarska, M., Tolusso, B., Benvenuto, R., Elmesmari, A., Canestri, S., Petricca, L., Mangoni, A., Fedele, A.L., DiMario, C., and et al. (2016). MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis. Nat. Commun. 7, 12970.

9. Schneider, E., Staffas, A., Röhrer, L., Malmberg, E.D., Ashouri, A., Krowiorz, K., Povirk, F., and Fesik, S.W. (2016). A microRNA expression signature gets. Cell 169, 431–443.

10. Wallace, J.A., Kagle, D.A., Eiring, A.M., Kim, C.N., Hu, R., Runtsch, M.C., Alexander, M., Huffaker, T.B., Lee, S.H., Patel, A.B., et al. (2017). miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response. Blood 129, 3074–3086.

11. Zhang, T., Davidson-Moncada, J.K., Mukherjee, P., Furman, R.R., Bhavsar, E., Chen, Z., Han, K., Kim, J., and et al. (2017). MicroRNA-155 regulates caspase kinase-1 gamma 2: a potential pathogenic role in chronic lymphocytic leukemia. Haematologica 102, 246–255.

12. Zhang, Y., Zhang, X., and Han, K. (2013). Histone H3.3 variant H3.3K27me3 is essential for glioma tumorigenesis. Nat. Commun. 4, 2257.

13. Nuñez, E., Staffas, A., Röhner, L., Malmberg, E.D., Ashouri, A., Krowiorz, K., Schneider, E., and Berger, S.L. (2000). Phosphorylation of serine 10 in histone H3 is functionally endowed by adenosines, indicates that thousands of human genes are microRNA targets. Nat. Commun. 10, 1239.

14. Wallace, J.A., Kagle, D.A., Eiring, A.M., Kim, C.N., Hu, R., Runtsch, M.C., Alexander, M., Huffaker, T.B., Lee, S.H., Patel, A.B., et al. (2017). miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response. Blood 129, 3074–3086.

15. Zhang, T., Davidson-Moncada, J.K., Mukherjee, P., Furman, R.R., Bhavsar, E., Chen, Z., Han, K., Kim, J., and et al. (2017). MicroRNA-155 regulates caspase kinase-1 gamma 2: a potential pathogenic role in chronic lymphocytic leukemia. Haematologica 102, 246–255.

16. Zhang, Y., Zhang, X., and Han, K. (2013). Histone H3.3 variant H3.3K27me3 is essential for glioma tumorigenesis. Nat. Commun. 4, 2257.

17. Zhang, T., Davidson-Moncada, J.K., Mukherjee, P., Furman, R.R., Bhavsar, E., Chen, Z., Han, K., Kim, J., and et al. (2017). MicroRNA-155 regulates caspase kinase-1 gamma 2: a potential pathogenic role in chronic lymphocytic leukemia. Haematologica 102, 246–255.

18. Zhang, Y., Zhang, X., and Han, K. (2013). Histone H3.3 variant H3.3K27me3 is essential for glioma tumorigenesis. Nat. Commun. 4, 2257.

19. Zhang, T., Davidson-Moncada, J.K., Mukherjee, P., Furman, R.R., Bhavsar, E., Chen, Z., Han, K., Kim, J., and et al. (2017). MicroRNA-155 regulates caspase kinase-1 gamma 2: a potential pathogenic role in chronic lymphocytic leukemia. Haematologica 102, 246–255.

20. Zhang, Y., Zhang, X., and Han, K. (2013). Histone H3.3 variant H3.3K27me3 is essential for glioma tumorigenesis. Nat. Commun. 4, 2257.

21. Zhang, T., Davidson-Moncada, J.K., Mukherjee, P., Furman, R.R., Bhavsar, E., Chen, Z., Han, K., Kim, J., and et al. (2017). MicroRNA-155 regulates caspase kinase-1 gamma 2: a potential pathogenic role in chronic lymphocytic leukemia. Haematologica 102, 246–255.

22. Zhang, Y., Zhang, X., and Han, K. (2013). Histone H3.3 variant H3.3K27me3 is essential for glioma tumorigenesis. Nat. Commun. 4, 2257.

23. Zhang, T., Davidson-Moncada, J.K., Mukherjee, P., Furman, R.R., Bhavsar, E., Chen, Z., Han, K., Kim, J., and et al. (2017). MicroRNA-155 regulates caspase kinase-1 gamma 2: a potential pathogenic role in chronic lymphocytic leukemia. Haematologica 102, 246–255.

24. Zhang, T., Davidson-Moncada, J.K., Mukherjee, P., Furman, R.R., Bhavsar, E., Chen, Z., Han, K., Kim, J., and et al. (2017). MicroRNA-155 regulates caspase kinase-1 gamma 2: a potential pathogenic role in chronic lymphocytic leukemia. Haematologica 102, 246–255.

25. Zhang, T., Davidson-Moncada, J.K., Mukherjee, P., Furman, R.R., Bhavsar, E., Chen, Z., Han, K., Kim, J., and et al. (2017). MicroRNA-155 regulates caspase kinase-1 gamma 2: a potential pathogenic role in chronic lymphocytic leukemia. Haematologica 102, 246–255.
38. Cao, R., and Zhang, Y. (2004). The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr. Opin. Genet. Dev. 14, 155–164.

39. Czermin, B., Melki, R., McCabe, D., Seitz, V., Imhof, A., and Pirrotta, V. (2002). Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell 111, 185–196.

40. Lee, W., Teckie, S., Wiesner, T., Ran, L., Prieto Granada, C.N., Lin, M., Zhu, S., Cao, Z., Liang, Y., Sbomner, A., et al. (2014). PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat. Genet. 46, 1227–1232.

41. Hansen, T.B., Jensen, T.I., Clausen, B.H., Bramsen, J.B., Finsen, B., Damgaard, C.K., and Kjems, J. (2013). Natural RNA circles function as efficient microRNA sponges. Nature 495, 384–388.

42. Cherubini, A., Barilani, M., Rossi, R.L., Jalal, M.M.K., Rusconi, F., Buono, G., Ragni, E., Cantarella, G., Simpson, H.A.R.W., Peault, B., and Lazzari, L. (2019). FOXP1 circular RNA sustains mesenchymal stem cell identity via microRNA inhibition. Nucleic Acids Res. 47, 5325–5340.

43. Li, Z., Huang, C., Bao, C., Chen, L., Lin, M., Wang, X., Zhong, G., Yu, B., Hu, W., Dai, L., et al. (2015). Exon-intron circular RNAs regulate transcription in the nucleus. Nat. Struct. Mol. Biol. 22, 256–264.

44. Du, W.W., Yang, W., Liu, E., Yang, Z., Dhalwal, P., and Yang, B.B. (2016). Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. Nucleic Acids Res. 44, 2846–2858.

45. Honda, R., Lowe, E.D., Dubinina, E., Skamnaki, V., Cook, A., Brown, N.R., and Johnson, L.N. (2005). The structure of cyclin E1/CDK2: implications for CDK2 activation and CDK2-independent roles. EMBO J. 24, 452–463.

46. Feng, Z., Xia, Y., Gao, T., Xu, F., Lei, Q., Peng, C., Yang, Y., Xue, Q., Hu, X., Wang, Q., et al. (2018). The antipsychotic agent trifluoperazine hydrochloride suppresses triple-negative breast cancer tumor growth and brain metastasis by inducing G0/G1 arrest and apoptosis. Cell Death Dis. 9, 1006.

47. Peng, C., Zeng, W., Su, J., Kuang, Y., He, Y., Zhao, S., Zhang, J., Ma, W., Bode, A.M., Dong, Z., and Chen, X. (2016). Cyclin-dependent kinase 2 (CDK2) is a key mediator for EGF-induced cell transformation mediated through the ELK4/c-Fos signaling pathway. Oncogene 35, 1170–1179.

48. Tang, J., Wang, F., Cheng, G., Si, S., Sun, X., Han, J., Yu, H., Zhang, W., Lv, Q., Wei, J.F., and Yang, H. (2018). Wilms’ tumor 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability. J. Exp. Clin. Cancer Res. 37, 40.

49. Abbas, T., and Dutta, A. (2009). p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 9, 400–414.

50. Karimian, A., Ahmadi, Y., and Yousef, B. (2016). Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst.) 42, 63–71.

51. Luo, J., Liu, K., Yao, Y., Sun, Q., Zheng, X., Zhu, B., Zhang, Q., Xu, L., Shen, Y., and Ren, B. (2019). DMBX1 promotes tumor proliferation and regulates cell cycle progression via repressing OTX2-mediated transcription of p21 in lung adenocarcinoma cell. Cancer Lett. 453, 45–56.

52. Sun, X., Hu, Y., Wu, J., Shi, L., Zhu, L., Xi, P.-W., Wei, J.-F., and Ding, Q. (2018). RBMS2 inhibits the proliferation by stabilizing P21 mRNA in breast cancer. J. Exp. Clin. Cancer Res. 37, 298.

53. Li, Z., Qiu, R., Qiu, X., and Tian, T. (2018). sNHS6 Promotes Tumor Growth via Repression of P21 in Colorectal Cancer. Cell. Physiol. Biochem. 49, 463–478.

54. Liu, Y.W., Xia, R., Lu, K., Xie, M., Yang, F., Sun, M., De, W., Wang, C., and Ji, G. (2017). LinctRNA-FEZ1F1-AS1 represses p21 expression to promote gastric cancer proliferation through LSD1-Mediated H3K4me2 demethylation. Mol. Cancer 16, 39.